Centiva Capital’s BioNTech BNTX Stock Holding History

Centiva Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$4.26M	–	1154
2025 Q2	$4.26M	Buy	+40,000	New	+$4.04M	0.07%	163
2024 Q1	–	Sell	-7,500	Closed	-$792K	–	1792
2023 Q4	$792K	Hold	7,500	–	–	0.02%	727
2023 Q3	$815K	Hold	7,500	–	–	0.02%	736
2023 Q2	$809K	Sell	7,500 -11,300	-60%	-$1.27M	0.02%	647
2023 Q1	$2.34M	Sell	18,800 -22,100	-54%	-$3.03M	0.06%	353
2022 Q4	$6.14M	Buy	40,900 +600	+1%	+$92.3K	0.17%	117
2022 Q3	$5.43M	Buy	40,300 +3,700	+10%	+$566K	0.1%	141
2022 Q2	$5.46M	Buy	36,600 +36,000	+6,000%	+$5.5M	0.13%	129
2022 Q1	$102K	Sell	600 -1,900	-76%	-$319K	﹤0.01%	1376
2021 Q4	$645K	Buy	2,500 +2,200	+733%	+$603K	0.01%	729
2021 Q3	$82K	Buy	+300	New	+$95.3K	0.01%	1071

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Centiva Capital's BNTX Position: Q2 2026 in Review

Centiva Capital sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 2,500 shares — an estimated $222K sold.

Centiva Capital first reported a position in BNTX in Q2 2021 and held it in 8 quarters. The position peaked at $1.41M in Q1 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Centiva Capital reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 2,500 BioNTech shares in Q2 2026, an estimated $222K.
Centiva Capital first reported a position in BioNTech in Q2 2021 and held it in 8 quarters.
Centiva Capital's BioNTech position peaked at $1.41M in Q1 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.